Neil McNaughton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Neil McNaughton has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Paul Glue
Department of Psychological Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
11 shared publications - Phoebe S.-H. Neo
Department of Psychology, University of Otago, Dunedin, New Zealand
10 shared publications - Calvin K. Young
Department of Psychology, University of Otago , Dunedin
9 shared publications - Shabah M. Shadli
Department of Psychology, University of Otago , Dunedin
8 shared publications Ming Ruan
Department Psychology and Brain Health Research Centre University of Otago Dunedin New Zealand
7 shared publications- Ben Beaglehole
Department of Psychological Medicine, University of Otago, Christchurch, New Zealand
5 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9)
Ketamine Dose and Duration Effects in Internalizing Disorders
The dose‐response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment‐resistant depression, post‐traumatic stress disorder, generalized and/or social anxiety, or obsessive‐compulsive disorder. For each disorder, they received single intramuscular doses of racemic ketamine (0.5 and 1.0 mg/kg) and a psychoactive control, using a three‐way within‐subject double‐blind active‐controlled cross‐over design. Intramuscular racemic ketamine doses of 0.5 and 1.0 mg/kg produced robust effects on diagnosis‐appropriate outcome scales for all these internalizing disorders, compared with psychoactive controls. These effects were most obvious at 24 h after dosing and noticeably smaller at 168 h. The magnitude of change after 1 mg/kg did not differ significantly from 0.5 mg/kg at either time point, and did not differ significantly between the internalizing disorders at 24 h. When combined with other ketamine dose‐response data, we propose that ketamine may have a narrow inverted‐U dose‐response profile (peaking in the regions of 0.5‐1.0 mg/kg) in patients with internalizing disorders.
- 16 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9)
Open AccessKetamine Dose and Duration Effects in Internalizing Disorders
The dose‐response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment‐resistant depression, post‐traumatic stress disorder, generalized and/or social anxiety, or obsessive‐compulsive disorder. For each disorder, they received single intramuscular doses of racemic ketamine (0.5 and 1.0 mg/kg) and a psychoactive control, using a three‐way within‐subject double‐blind active‐controlled cross‐over design. Intramuscular racemic ketamine doses of 0.5 and 1.0 mg/kg produced robust effects on diagnosis‐appropriate outcome scales for all these internalizing disorders, compared with psychoactive controls. These effects were most obvious at 24 h after dosing and noticeably smaller at 168 h. The magnitude of change after 1 mg/kg did not differ significantly from 0.5 mg/kg at either time point, and did not differ significantly between the internalizing disorders at 24 h. When combined with other ketamine dose‐response data, we propose that ketamine may have a narrow inverted‐U dose‐response profile (peaking in the regions of 0.5‐1.0 mg/kg) in patients with internalizing disorders.
- Open Access
- 25 August 2026
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 191
Psychological traits and their explanation: A 20-year perspective from Reinforcement Sensitivity Theory
- 25 August 2026
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 191
Open AccessPsychological traits and their explanation: A 20-year perspective from Reinforcement Sensitivity Theory
- Open Access
- 20 July 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1795436
Neural mechanisms underlying cognitive inflexibility in obsessive-compulsive disorder: a review
Cognitive inflexibility, a reduced capacity to shift mental set or update behavior when circumstances change, is a significant feature of obsessive-compulsive disorder (OCD). However, while cognitive inflexibility is superficially a coherent entity, it appears to engage a range of distinct cognitive processes. This raises the question of how far deficits in different tasks involve the same core dysfunction and how far the dysfunctions are unique but superficially have similar results. Here we detail the neural basis of OCD deficits across eight tasks that challenge different aspects of cognitive flexibility: set-shifting (Wisconsin Card Sorting Task, Intra/Extra-Dimensional Set Shift), feedback adaptation (Reversal Learning), interference control (Stroop Color and Word Test), response inhibition (Go/No-Go Task and Stop Signal Task), working memory updating (n-back Task), and value-based flexibility (Delay Discounting Task). Cognitive inflexibility in OCD appears linked to functional abnormalities in a largely shared set of core structures (anterior cingulate cortex, caudate nucleus, orbital frontal cortex, and prefrontal cortex) and less shared ‘peripheral’ structures (putamen, thalamus, parietal cortex), based on cross-task convergence of OCD-specific abnormalities. Even the shared core appears to engage multiple interconnected neural networks. The cortico-striato-thalamo-cortical network appears central, and the salience network and the default mode network also contribute with indirect, task-varying effects on peripheral parts of each. Peripheral areas are less consistently involved but appear to contribute to OCD nonetheless. Cognitive inflexibility in OCD appears to involve failure of interaction between multiple networks rather than dysfunction in any single system.
- 20 July 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1795436
Open AccessNeural mechanisms underlying cognitive inflexibility in obsessive-compulsive disorder: a review
Cognitive inflexibility, a reduced capacity to shift mental set or update behavior when circumstances change, is a significant feature of obsessive-compulsive disorder (OCD). However, while cognitive inflexibility is superficially a coherent entity, it appears to engage a range of distinct cognitive processes. This raises the question of how far deficits in different tasks involve the same core dysfunction and how far the dysfunctions are unique but superficially have similar results. Here we detail the neural basis of OCD deficits across eight tasks that challenge different aspects of cognitive flexibility: set-shifting (Wisconsin Card Sorting Task, Intra/Extra-Dimensional Set Shift), feedback adaptation (Reversal Learning), interference control (Stroop Color and Word Test), response inhibition (Go/No-Go Task and Stop Signal Task), working memory updating (n-back Task), and value-based flexibility (Delay Discounting Task). Cognitive inflexibility in OCD appears linked to functional abnormalities in a largely shared set of core structures (anterior cingulate cortex, caudate nucleus, orbital frontal cortex, and prefrontal cortex) and less shared ‘peripheral’ structures (putamen, thalamus, parietal cortex), based on cross-task convergence of OCD-specific abnormalities. Even the shared core appears to engage multiple interconnected neural networks. The cortico-striato-thalamo-cortical network appears central, and the salience network and the default mode network also contribute with indirect, task-varying effects on peripheral parts of each. Peripheral areas are less consistently involved but appear to contribute to OCD nonetheless. Cognitive inflexibility in OCD appears to involve failure of interaction between multiple networks rather than dysfunction in any single system.
- Open Access
- 6 July 2026
- Published by Cambridge University Press (CUP) in Personality Neuroscience
- Vol. 9, e4
A four-factor model of psychopathy assessed via neural reinforcement sensitivity theory
Reinforcement sensitivity theory (RST) most clearly relates to internalizing disorders. But a weak behavioural inhibition system (BIS as defined by RST) could underlie externalising, in general, and psychopathy in particular (Fowles, 1980). Conventional “rationally derived” RST scales (rRST) are not anchored in neurally defined RST systems (nRST). So, here, we use both rRST and nRST measures to assess psychopathy traits. We operationalised psychopathy via a four-factor model ( affective | interpersonal | disinhibition | boldness ). We operationalised rRST via the Heym, Ferguson & Lawrence (2008) updated version of Carver and White’s (1994) BIS/BAS scales ( BAS | BIS | FFFS) . We operationalised nRST (goal inhibition system, GIS; goal repulsion system, GRS) via previously validated (Shadli et al., 2021) rhythmic power in the stop signal task (SST) and (goal approach system, GAS) via previously validated ERPs in the doors task. Initial bivariate correlations of psychopathy factors with rRST scales were as expected. We found no significant associations between psychopathy factors and nRST measures. A series of post hoc exploratory repeated measures ANOVAs guarded against non-linearity between psychopathy and nRST constructs. These found that: (1) Disinhibition traits might be explained (unexpectedly) by increased sensitivity in the GIS (i.e., conflict) and GRS (i.e., repulsion) and decreased sensitivity in the GAS (i.e., attraction). (2) Affective traits might be explained, as expected, by decreased sensitivity in the GIS and GRS. But an unexpected positive association was also found in the alpha frequency range for the GRS. So, nRST systems (particularly GIS) do not explain psychopathy. rRST scales were more aligned with expectations but were explained via their “rational” basis not RST per se. Unlike internalizing, nRST does not appear strongly related to externalising disorders in general and psychopathy in particular. rRST appears distinct from nRST.
- 6 July 2026
- Published by Cambridge University Press (CUP) in Personality Neuroscience
- Vol. 9, e4
Open AccessA four-factor model of psychopathy assessed via neural reinforcement sensitivity theory
Reinforcement sensitivity theory (RST) most clearly relates to internalizing disorders. But a weak behavioural inhibition system (BIS as defined by RST) could underlie externalising, in general, and psychopathy in particular (Fowles, 1980). Conventional “rationally derived” RST scales (rRST) are not anchored in neurally defined RST systems (nRST). So, here, we use both rRST and nRST measures to assess psychopathy traits. We operationalised psychopathy via a four-factor model ( affective | interpersonal | disinhibition | boldness ). We operationalised rRST via the Heym, Ferguson & Lawrence (2008) updated version of Carver and White’s (1994) BIS/BAS scales ( BAS | BIS | FFFS) . We operationalised nRST (goal inhibition system, GIS; goal repulsion system, GRS) via previously validated (Shadli et al., 2021) rhythmic power in the stop signal task (SST) and (goal approach system, GAS) via previously validated ERPs in the doors task. Initial bivariate correlations of psychopathy factors with rRST scales were as expected. We found no significant associations between psychopathy factors and nRST measures. A series of post hoc exploratory repeated measures ANOVAs guarded against non-linearity between psychopathy and nRST constructs. These found that: (1) Disinhibition traits might be explained (unexpectedly) by increased sensitivity in the GIS (i.e., conflict) and GRS (i.e., repulsion) and decreased sensitivity in the GAS (i.e., attraction). (2) Affective traits might be explained, as expected, by decreased sensitivity in the GIS and GRS. But an unexpected positive association was also found in the alpha frequency range for the GRS. So, nRST systems (particularly GIS) do not explain psychopathy. rRST scales were more aligned with expectations but were explained via their “rational” basis not RST per se. Unlike internalizing, nRST does not appear strongly related to externalising disorders in general and psychopathy in particular. rRST appears distinct from nRST.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 29 (7)
Ketamine effects on EEG and their links to therapy differ across treatment-resistant major depression, post-traumatic stress disorder, and obsessive-compulsive disorder
Introduction: Neurotic disorders—major depressive disorder (MDD), panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and specific phobia—have differing pharmaceutical profiles. But all, even when resistant to conventional treatment (TR), respond quickly to low-dose (0.5-1.0 mg/kg I.M.) ketamine. We explore the variation in the neural effects of ketamine across its treatments of TR-MDD, TR-PTSD, and TR-OCD. Materials and methods: We recorded 10 min of resting frontal activity and diagnosis-related scale measures, before and 2 h after fentanyl (50 mcg) or ketamine (0.5 or 1.0 mg/kg, I.M.) counterbalanced across 3 sessions at least a week apart. Average power spectra were calculated for delta, theta, alpha1, alpha2, beta, and gamma bands. Analysis of variance compared TR-PTSD (20 F, 2 M) with TR-MDD (12 F, 13 M). Preliminary TR-OCD (5 F, 2 M) data were also obtained. Results: TR-PTSD patients showed dose- and band frequency-dependent electroencephalography (EEG) power changes (particularly alpha at 0.05 mg/kg), while TR-MDD patients did not. TR-OCD differed qualitatively from both. The correlation of power change with score change was maximal for different bands and electrodes across the different scales (Impact of Events Scale-Revised, Montgomery-Åsberg Depression Rating Scale, Hospital Anxiety and Depression Scales, Hamilton Anxiety Scale, Fear Questionnaire, and Yale-Brown Obsessive-Compulsive Scale). Discussion: Ketamine effects and their therapeutic links vary in band and site with conventional diagnosis—including previous TR anxiety results. The EEG results appear to detect changes in the disorder-specific systems that conventional treatments target selectively and directly and these appear to require a ketamine-sensitive factor (as a “double hit”) to generate disorder.
- 1 July 2026
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 29 (7)
Open AccessKetamine effects on EEG and their links to therapy differ across treatment-resistant major depression, post-traumatic stress disorder, and obsessive-compulsive disorder
Introduction: Neurotic disorders—major depressive disorder (MDD), panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and specific phobia—have differing pharmaceutical profiles. But all, even when resistant to conventional treatment (TR), respond quickly to low-dose (0.5-1.0 mg/kg I.M.) ketamine. We explore the variation in the neural effects of ketamine across its treatments of TR-MDD, TR-PTSD, and TR-OCD. Materials and methods: We recorded 10 min of resting frontal activity and diagnosis-related scale measures, before and 2 h after fentanyl (50 mcg) or ketamine (0.5 or 1.0 mg/kg, I.M.) counterbalanced across 3 sessions at least a week apart. Average power spectra were calculated for delta, theta, alpha1, alpha2, beta, and gamma bands. Analysis of variance compared TR-PTSD (20 F, 2 M) with TR-MDD (12 F, 13 M). Preliminary TR-OCD (5 F, 2 M) data were also obtained. Results: TR-PTSD patients showed dose- and band frequency-dependent electroencephalography (EEG) power changes (particularly alpha at 0.05 mg/kg), while TR-MDD patients did not. TR-OCD differed qualitatively from both. The correlation of power change with score change was maximal for different bands and electrodes across the different scales (Impact of Events Scale-Revised, Montgomery-Åsberg Depression Rating Scale, Hospital Anxiety and Depression Scales, Hamilton Anxiety Scale, Fear Questionnaire, and Yale-Brown Obsessive-Compulsive Scale). Discussion: Ketamine effects and their therapeutic links vary in band and site with conventional diagnosis—including previous TR anxiety results. The EEG results appear to detect changes in the disorder-specific systems that conventional treatments target selectively and directly and these appear to require a ketamine-sensitive factor (as a “double hit”) to generate disorder.
- Open Access
- 15 February 2026
- Published by Wiley in Journal of the Royal Society of New Zealand
- Vol. 56 (1) , e70002
Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments
The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post‐traumatic stress disorder, and obsessive–compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand‐based work developing EEG biomarkers and novel treatments. Working at the University of Otago, we have developed an anxiety disorder biomarker and shown its potential to detect anxiety resistant to conventional treatments. Others have started similar work on depression biomarkers. We have also found that ketamine is a novel treatment for treatment‐resistant neurotic disorders in general and have provided a “double hit” hypothesis of the mechanisms involved. Muthukumaraswamy and coworkers at the University of Auckland and elsewhere have obtained similar results with ketamine, LSD, and psilocybin, and we, along with them, have demonstrated treatment‐related effects on EEG. These linked developments, potentially supplemented with psychotherapy, should open the way to quicker acting, broad ranging, effective treatment of neurotic disorders. With the our recent more purely practical development of oral tablet delivery, which will allow home dosing, the future for the treatment of neurotic disorders looks bright.
- 15 February 2026
- Published by Wiley in Journal of the Royal Society of New Zealand
- Vol. 56 (1) , e70002
Open AccessHope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments
The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post‐traumatic stress disorder, and obsessive–compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand‐based work developing EEG biomarkers and novel treatments. Working at the University of Otago, we have developed an anxiety disorder biomarker and shown its potential to detect anxiety resistant to conventional treatments. Others have started similar work on depression biomarkers. We have also found that ketamine is a novel treatment for treatment‐resistant neurotic disorders in general and have provided a “double hit” hypothesis of the mechanisms involved. Muthukumaraswamy and coworkers at the University of Auckland and elsewhere have obtained similar results with ketamine, LSD, and psilocybin, and we, along with them, have demonstrated treatment‐related effects on EEG. These linked developments, potentially supplemented with psychotherapy, should open the way to quicker acting, broad ranging, effective treatment of neurotic disorders. With the our recent more purely practical development of oral tablet delivery, which will allow home dosing, the future for the treatment of neurotic disorders looks bright.
- 31 August 2025
- Published by Springer Nature
- p. 423-444
Linking the Biological Marker Goal-Conflict Specific Rhythmicity (GCSR) and Anxiety Disorder
- 31 August 2025
- Published by Springer Nature
- p. 423-444
Linking the Biological Marker Goal-Conflict Specific Rhythmicity (GCSR) and Anxiety Disorder
- Open Access
- 5 June 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 39 (6) , 571-576
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder
Background: We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. Method: All participants from the original study were eligible to receive a 6-week open-label course of oral ketamine once-thrice weekly. Racemic ketamine for injection was diluted in orange juice and sipped over 30–60 min. Dose amount and frequency were adjusted individually to maximise benefits and tolerability. Effectiveness was assessed by disorder-specific scales. Side effects and tolerability were assessed using reported adverse events and scales for dissociation and urinary/bladder symptoms. Results: Seventeen participants with TR-D, 18 participants with TR-PTSD and 8 participants with TR-OCD commenced oral ketamine. Nine participants with TR-D, 16 participants with TR-PTSD and 5 participants with TR-OCD completed all 6 weeks of dosing. Ketamine dose increased over time from 1–1.5 mg/kg to 1.5–2.5 mg/kg, with a dosing frequency of 1–3 times/week, with an average total dose rising from 1.9 to 3.0 mg/kg/week over the first 3 weeks. Symptom rating scores for TR-D, TR-PTSD and TR-OCD were low at week 1 of oral dosing (compared to scores at entry into the original study) and remained low throughout the six-week course of oral ketamine. Oral ketamine was well tolerated with minimal side effects. Conclusion: The 6-week extension of oral ketamine appeared to sustain improvements for TR-D, TR-PTSD and TR-OCD. Oral ketamine was well tolerated and offers an alternative option for patients, researchers and clinicians.
- 5 June 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 39 (6) , 571-576
Open AccessSix weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder
Background: We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. Method: All participants from the original study were eligible to receive a 6-week open-label course of oral ketamine once-thrice weekly. Racemic ketamine for injection was diluted in orange juice and sipped over 30–60 min. Dose amount and frequency were adjusted individually to maximise benefits and tolerability. Effectiveness was assessed by disorder-specific scales. Side effects and tolerability were assessed using reported adverse events and scales for dissociation and urinary/bladder symptoms. Results: Seventeen participants with TR-D, 18 participants with TR-PTSD and 8 participants with TR-OCD commenced oral ketamine. Nine participants with TR-D, 16 participants with TR-PTSD and 5 participants with TR-OCD completed all 6 weeks of dosing. Ketamine dose increased over time from 1–1.5 mg/kg to 1.5–2.5 mg/kg, with a dosing frequency of 1–3 times/week, with an average total dose rising from 1.9 to 3.0 mg/kg/week over the first 3 weeks. Symptom rating scores for TR-D, TR-PTSD and TR-OCD were low at week 1 of oral dosing (compared to scores at entry into the original study) and remained low throughout the six-week course of oral ketamine. Oral ketamine was well tolerated with minimal side effects. Conclusion: The 6-week extension of oral ketamine appeared to sustain improvements for TR-D, TR-PTSD and TR-OCD. Oral ketamine was well tolerated and offers an alternative option for patients, researchers and clinicians.
- 1 March 2025
- Published by American Psychological Association (APA) in Motivation Science
- Vol. 11 (1) , 1-17
The legacies of the neuropsychology of anxiety for Reinforcement Sensitivity Theory.
- 1 March 2025
- Published by American Psychological Association (APA) in Motivation Science
- Vol. 11 (1) , 1-17
The legacies of the neuropsychology of anxiety for Reinforcement Sensitivity Theory.
- 20 December 2024
- Published by Wiley in Hippocampus
- Vol. 35 (1) , e23653
Linking Anxiolytic Action to Hippocampal “Theta”—A Personal History
This paper provides a personal history of work starting with the discovery that anxiolytic drugs reduce hippocampal theta frequency. It includes parallel work on septal elicitation of theta carried out in Jeffrey Gray's laboratory in Oxford; a statement of my original scientific perspective on the work; and a description of later work in my laboratory in New Zealand confirming the function of theta rhythmicity per se and its mediation of the effects of anxiolytic drugs on behavior. I finish with comments on risk management with such experiments and their use in larger scale theory development.
- 20 December 2024
- Published by Wiley in Hippocampus
- Vol. 35 (1) , e23653
Linking Anxiolytic Action to Hippocampal “Theta”—A Personal History
This paper provides a personal history of work starting with the discovery that anxiolytic drugs reduce hippocampal theta frequency. It includes parallel work on septal elicitation of theta carried out in Jeffrey Gray's laboratory in Oxford; a statement of my original scientific perspective on the work; and a description of later work in my laboratory in New Zealand confirming the function of theta rhythmicity per se and its mediation of the effects of anxiolytic drugs on behavior. I finish with comments on risk management with such experiments and their use in larger scale theory development.